There are 2867 resources available
Invited Discussant LBA20, 211MO and 212MO
Presenter: Shaheenah Dawood
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Slides
Webcast
Invited Discussant LBA40 and 785O
Presenter: Olivier Michielin
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Slides
Webcast
734MO - Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy
Presenter: Benjamin Fairfax
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1316O - Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network
Presenter: Jean-Yves Blay
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant 732MO, 733MO and 734MO
Presenter: Sebastian Kobold
Session: Mini Oral session: Investigational immunotherapy
Resources:
Slides
Webcast
Invited Discussant 1314O, 1315O and 1316O
Presenter: Christophe Massard
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Haematological malignancies
Resources:
Webcast
1204MO - PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Presenter: David Tougeron
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
213MO - Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
Presenter: Monica Arnedos
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1205MO - Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
Presenter: Geoffrey Ku
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast